Skip to main content
Premium Trial:

Request an Annual Quote

Gamida for Life Buys Elitech's Microarray Technology

NEW YORK (GenomeWeb News) – Gamida For Life Group has acquired electronic microarray technologies from the Elitech Group, a private group of in vitro diagnostics and reagent companies, for an undisclosed sum, Elitech said today.

Paris-based Elitech said that the intellectual property and tangible assets Gamida bought was from Epoch Bioscience, part of Elitech's Wescor division, and were originally acquired from Nanogen in July, 2009, for $25.7 million.

The deal covers the all of the assets associated with the NC400 electronic microarray product line, which is a nucleic acid profiling platform used in SNP applications.

The technologies will be developed and applied within the Gamida for Life Group, mainly by Gamidor Diagnostics and Savyon Diagnostics, Elitech Group President and Founder Pierre Debiais, said in a statement.

Gamida "has developed a variety of focused applications for the NC400 and we believe that our divestiture of these former Nanogen assets to it will allow the full and appropriate realization of the potential of this cutting-edge technology," Debiais said.

Debiais said that Elitech plans to focus on its core strengths and to enhance its molecular diagnostics and real-time PCR activities.

Financial terms of the agreement were not released.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.